Efficacy and Safety of Retrograde Intraarticular Injection, Topical Soaking of Tranexamic Acid (TXA), or Placebo in Femoral Neck Fractured Patients Undergoing Cementless Bipolar Hemiarthroplasty

Launched by KING CHULALONGKORN MEMORIAL HOSPITAL · Feb 25, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment for elderly patients who have suffered a femoral neck fracture, which is a type of hip injury. The study aims to find out if using a medication called tranexamic acid (TXA) can help reduce the need for blood transfusions during a specific surgical procedure known as cementless bipolar hemiarthroplasty. Participants will either receive the TXA through an injection or by soaking it on the skin, while some will receive a placebo (a treatment with no active medication) for comparison.

To be eligible for the trial, participants need to be over 60 years old, have a femoral neck fracture from a low-energy accident (like a fall), and be able to walk at home. They must also be scheduled for the surgery at a specific hospital. However, those with certain conditions, like allergies to TXA, previous hip surgeries, or blood disorders, cannot participate. If you join the trial, you'll be contributing to important research that could improve care for future patients with similar injuries.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Elderly patients (age \> 60 years)
• • Femoral neck fractures from low energy mechanism
• • Household ambulator
• • Undergoing cementless bipolar hemiarthroplasty at KCMH
• • Informed consent
• Exclusion Criteria:
• • Allergy to TXA
• • History of VTE
• • History of hip surgery, pathological fracture, hip infection
• • Congenital or acquired coagulopathy
• • Hb \< 10 g/dL or Platelet \< 140,000